S'abonner

Management of chronic obstructive pulmonary disease in the Middle East and North Africa: Results of the BREATHE study - 04/01/13

Doi : 10.1016/S0954-6111(12)70013-6 
Majdy Idrees a, Marie-Louise Koniski b, Samya Taright c, Naeem Shahrour d, Mehmet Polatli e, Ali Ben Kheder f, Ashraf Alzaabi g, Ghali Iraqi h, Adel Khattab i, Arshad Javed j, Nauman Rashid k, Abdelkader El Hasnaoui k, , A

on behalf of the BREATHE Study GroupB

  BREATHE Steering Committee members (in alphabetical order of names): Ashraf Alzaabi, Zayed Military Hospital, Abu Dhabi, UAE; Majed Beji, La Rabta Hospital, Tunis, Tunisia; Ali Ben Kheder, Abderrahmane Mami Hospital, Tunis, Tunisia; Majdy Idrees, Riyadh Military Hospital, Riyadh, Saudi Arabia; Ghali Iraqi, Moulay Youssef Hospital, Rabat, Morocco; Arshad Javed, Lady Reading Hospital, Peshawar, Pakistan; Javaid Ahmed Khan, Aga Khan University Hospital, Karachi, Pakistan; Adel Khattab, Ain Shams University, Cairo, Egypt; Marie Louise Koniski, Lebanese American University, Beirut, Lebanon; Bassam Mahboub, University of Sharjah, Sharjah, UAE; Salim Nafti, Mustapha Bacha Hospital, Algiers, Algeria; Nathir M. Obeidat, University of Jordan, Amman, Jordan; Mehmet Polatli, Adnan Menderes University, Aydin, Turkey; Abdullah Sayiner, Ege University, Izmir, Turkey; Naem Shahrour, Alasaad University Hospital, Damascus, Syria; Mohamed Awad Tageldin, Ain Shams University, Cairo, Egypt; Samya Taright, Bab-El-Oued Hospital, Algiers, Algeria; Esra Uzaslan, Uludag University Medical Faculty, Bursa, Turkey; Siraj Wali, King Abdulaziz University, Jeddah, Saudi Arabia.BREATHE core team members: Abdelkader El Hasnaoui, GlaxoSmithKline, Dubai, UAE; Nauman Rashid, GlaxoSmithKline, Dubai, UAE; Aïcha Lahlou, MS Health, Rabat, Morocco; Adam Doble, Foxymed, Paris, France, Hocine Salhi, Foxymed, Paris, France and Chakib Nejjari Faculty of Medicine of Fez, Fez, Morocco.

a Riyadh Military Hospital, Riyadh, Saudi Arabia 
b Lebanese American University, Beirut, Lebanon 
c Bab-El-Oued Hospital, Algiers, Algeria 
d Alasaad University Hospital, Damascus, Syria 
e Adnan Menderes University, Aydin, Turkey 
f Abderrahmane Mami Hospital, Tunis, Tunisia 
g Zayed Military Hospital, Abu Dhabi, UAE 
h Moulay Youssef Hospital, Rabat, Morocco 
i Ain Shams University, Cairo, Egypt 
j Lady Reading Hospital, Peshawar, Pakistan 
k GlaxoSmithKline, Dubai, UAE 

* Corresponding author. Dr Abdelkader El Hasnaoui, GlaxoSmithKline, PO Box 50199, Dubai, United Arab Emirates. Tel.: +971 4409 6305; fax: +971 4332 3071

Summary

Chronic obstructive pulmonary disease (COPD) is a potentially severe chronic progressive respiratory condition requiring long-term treatment and frequently involving episodic hospitalisations to manage exacerbations. The objective of this analysis was to document diagnosis, evaluation, treatment and management of COPD-related respiratory symptoms in 1,392 subjects fulfilling an epidemiological definition of COPD identified in a general population sample of 62,086 individuals aged ≥ 40 years in ten countries in the Middle East and North Africa region (Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Syria, Tunisia, Turkey and United Arab Emirates), together with Pakistan. 442 subjects (31.8%) claimed to have received a diagnosis of COPD from a physician and 287 (20.6%) had undergone spirometry in the previous year. Use of specific treatments for respiratory symptoms was reported by 218 subjects (15.7%). Use of inhaled long-acting bronchodilators together with corticosteroids (53 subjects; 3.8%) and use of oxygen therapy (31 subjects; 2.3%) was very low. 852 subjects (61.2%) had consulted a physician about their respiratory condition at least once in the previous year, with a mean number of consultations of 3.4±3.6. Moreover, 284 subjects (20.4%) had been hospitalised overnight for their COPD, with a mean of 2.3±3.7 hospitalisations per year. Use of all healthcare resources was significantly higher (p < 0.001) in subjects with CAT scores ≥10 than in those with scores < 10, and greater in those with exacerbations than in those without. In conclusion, COPD in the region is under-diagnosed, inadequately evaluated and inadequately treated. Nonetheless, COPD symptoms are responsible for considerable healthcare consumption, with high levels of physician consultation and hospitalisation.

Le texte complet de cet article est disponible en PDF.

Keywords : COPD, Management, Middle East, North Africa, Diagnosis, Treatment


Plan


 Conflict of interest statement
MI has received honoraria from GlaxoSmithKline Laboratories for his contribution to the BREATHE study and has received speaking honoraria from AstraZeneca, Novartis, Sanofi, MSD, Pfizer, Actelion and Bayer. M-LK, ST, NS, MP, ABK, AA, GI, AK and AJ have received honoraria from GlaxoSmithKline Laboratories for their contribution to the BREATHE study. NR and AEH are employees of GlaxoSmithKline Laboratories, which funded the BREATHE study and market a number of treatments for COPD.


© 2012  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 106 - N° S2

P. S33-S44 - décembre 2012 Retour au numéro
Article précédent Article précédent
  • Distribution of COPD-related symptoms in the Middle East and North Africa: Results of the BREATHE study
  • Mohamed Awad Tageldin, Salim Nafti, Javaid Ahmed Khan, Chakib Nejjari, Majed Beji, Bassam Mahboub, Nathir M. Obeidat, Esra Uzaslan, Abdullah Sayiner, Siraj Wali, Nauman Rashid, Abdelkader El Hasnaoui, on behalf of the BREATHE Study Group B
| Article suivant Article suivant
  • The burden of chronic obstructive pulmonary disease in the Middle East and North Africa: Results of the BREATHE study
  • Esra Uzaslan, Bassam Mahboub, Majed Beji, Chakib Nejjari, Mohamed Awad Tageldin, Javaid Ahmed Khan, Salim Nafti, Nathir M. Obeidat, Abdullah Sayiner, Siraj Wali, Nauman Rashid, Abdelkader El Hasnaoui, on behalf of the BREATHE Study Group B

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.